These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. Cerosaletti K; Schneider A; Schwedhelm K; Frank I; Tatum M; Wei S; Whalen E; Greenbaum C; Kita M; Buckner J; Long SA PLoS One; 2013; 8(12):e83811. PubMed ID: 24376757 [TBL] [Abstract][Full Text] [Related]
11. Relationship between Multiple Sclerosis-Associated Buhelt S; Søndergaard HB; Oturai A; Ullum H; von Essen MR; Sellebjerg F Cells; 2019 Jun; 8(6):. PubMed ID: 31242590 [TBL] [Abstract][Full Text] [Related]
12. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy. Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872 [TBL] [Abstract][Full Text] [Related]
13. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. Michel L; Berthelot L; Pettré S; Wiertlewski S; Lefrère F; Braudeau C; Brouard S; Soulillou JP; Laplaud DA J Clin Invest; 2008 Oct; 118(10):3411-9. PubMed ID: 18769633 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M; J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Sotirchos ES; Bhargava P; Eckstein C; Van Haren K; Baynes M; Ntranos A; Gocke A; Steinman L; Mowry EM; Calabresi PA Neurology; 2016 Jan; 86(4):382-90. PubMed ID: 26718578 [TBL] [Abstract][Full Text] [Related]
16. Gene regulation by 1,25-dihydroxyvitamin D3 in CD4+CD25+ cells is enabled by IL-2. Gorman S; Judge MA; Hart PH J Invest Dermatol; 2010 Oct; 130(10):2368-76. PubMed ID: 20574434 [TBL] [Abstract][Full Text] [Related]
17. A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. Goldberg R; Clough JN; Roberts LB; Sanchez J; Kordasti S; Petrov N; Hertweck A; Lorenc A; Jackson I; Tasker S; Appios A; Omer O; Parkes M; Prescott N; Jenner RG; Irving PM; Lord GM J Crohns Colitis; 2021 Dec; 15(12):2054-2065. PubMed ID: 34120187 [TBL] [Abstract][Full Text] [Related]
18. Vitamin D Rolf L; Muris AH; Bol Y; Damoiseaux J; Smolders J; Hupperts R J Neurol Sci; 2017 Jul; 378():30-35. PubMed ID: 28566173 [TBL] [Abstract][Full Text] [Related]
19. [Combination of CD4+ CD25+ regulatory T cell and costimulatory pathway blockade inhibits acute rejection after liver transplantation: experiment with rats]. Shi LB; Zhang HW; Peng CH Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):942-6. PubMed ID: 17650415 [TBL] [Abstract][Full Text] [Related]
20. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]